Trials / Unknown
UnknownNCT05395845
Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2
Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2 Smell Disorders
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Aya abdelnasser hassani · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study will be conducted to evaluate : The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.
Detailed description
Smell is essential sensory function for good quality of life as its preservation helps in identifying several harmful odors . Viral URTIs can lead to olfactory disorders of varying degree and duration 70% of URTI caused by rhinovirus, adenovirus ,influenza and parainfluanza virus Smell disorders are divided into two types Quantitative (anosmia and hyposmia) Qualitative (parosmia and phantosmia) Anosmia is a total loss of smell . hyposmia is a decrease in the sense of smell. parosmia is a distortion of the smell in presence of an existing stimulus . Phantosmia (Cacosmia) is distortion of the smell in absence of an existing stimulus severe acute respiratory syndrome coronavirus2 (SARS-coV-2)which is a global pandemic started in china 2019 one of respiratory tract infection that affect olfaction and cause varying types of smell impairment. Smell disorders seem to be more common in SARS-coV2 than other respiratory infections as in some patient persist for long time after resolution of respiratory symptoms Current evidence suggest that olfactory impairment results from propensity of SARS-coV2 for neuroinvasion and neurotrophic activities . Majority of patients experience some level of smell impairment most often temporary as olfactory neuroepithelium has regenerative power . European study published on 16 July 2020 reported that some patient affected by SARS -coV2 come solely with olfactory symptoms and most of patient recovered within 2 weeks ,smell not recovered in one quarter of patient 15 Once olfactory dysfunction persists more than 2 weeks a therapy should be considered to avoid persistent impairment of smell One of therapies can be used in ttt of smell disorders ( Platelet \_rich plasma) PRP is a process in which a small amount of blood from test subject is separated by special centrifugation process. PRP contains many growth factor which have a neuroregenerative feature as well as therapeutic effect
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | platelets rich plasma | local ingection of platelets rich plasma |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2022-12-01
- Completion
- 2023-01-01
- First posted
- 2022-05-27
- Last updated
- 2022-05-27
Source: ClinicalTrials.gov record NCT05395845. Inclusion in this directory is not an endorsement.